SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4C for the consolidated group for the first quarter of FY 2021.
Highlights
• TGA approved registration of ZolpiMist®
• Australian patent granted for anagrelide
• Hypothesis for oral spray of anagrelide confirmed
• Successful capital raise of $4.1m
• End of period cash balance of $1.5m plus $2m held in term deposit
For more information, download the attached PDF.
Download this document
